In this paper I examine some of the factors influencing technology development and attempt to explain whether CLIA '88 enhances the opportunities or exacerbates the problems for U.S.-based technology development. The viewpoint I express is concentrated on the clinical chemistry segment of the diagnostics arena.
The Need for New Legislation Clinical chemistry in the U.S. entered the last decade of the 20th century with a most impressive record of technological development relative to other branches of pathology. Whatever criteria are used to measure progress, the achievements in instrumentation, reagents, and diagnostic kits have been considerable. This progress has been due, to a great extent, to realistic levels of bureaucracy (regulations on in-vitro diagnostics and good manufacturing practices enforced by the FDA) and a well-informed profession capable of selecting the appropriate product in a competitive marketplace. Exist- ing regulations, FDA vigilance, and a responsible industry have ensured the withdrawal from the market of numerous ill-conceived products before any large-scale detriment to patient care. It is difficult to see how the new legislation of CLIA '88, with its demanding requirements for calibration and classifications of tests into categories that ignore technological achievement, will bring about measurable improvement in test performance.
Regulations primarily written to inhibit the perfor- 
The Process of Diagnostic Product Development
There are many stages in the development of a diagnostic product, and many factors influence priorities for the diagnostics manufacturer. For most manufacturers, there is a choice of three areas on which to concentrate expenditures: product reliability of existing products, product extension for existing products, and new product development. The first two areas carry little technological risk and have a high chance of revenue enhancement. The third is high risk technologically and cannot ensure a return of revenue.
Unfortunately, U.S. industry has emphasized the first two at the expense of the third, owing to the insistence on short-term gain. Moreover, the career risk encountered by marketing and research and development executives in the U.S. diagnostic industry when they concentrate on new-product development is such that the practice is often deemed unwise.
In this environment, where risk of job security for the non-U.S. executive is less and where the regulations abroad are less demanding, the development of new products is viewed more favorably by European and Asian corporations. The marked delay in the market introduction of the serum a-fetoprotein test in the U.S., nearly a decade after its introduction in Europe, illustrates the problem. Many experts are now concerned that the new (and effective) testing methods for human immunodeficiency virus and hepatitis C may be used widely throughout the rest of the world well before American patients can benefit from the tests. It is essential that regulations such as CLIA '88 do not become a further hurdle to new-product development, thus threatening a well-established leadership position in diagnostic-product development.
Influence of Legislation on the Diagnostic Product
The existing requirements for new-product introduction, enforced by the FDA, are embodied in two major approval schemes, the 510(k) or Pre-Market Approval (PMA) regulations.
The requirements ensure that the FDA can assess the performance and safety features of new products before giving approval for their release to the market. While the U.S. remains the largest marketplace for diagnostic products, these requirements will continue to play a key role in product development. The characteristics that point to success for certain established diagnostic products that eRjoy long life cycles have little to do with FDA regulations, but more to do with features of the product that enhance and prolong market position. Product demise is rarely ascribable to regulation, but rather to the perception of quality, value, and performance as viewed by the user.
Users' Perception of CLIA '88 Benefits

Few experienced laboratorians
have not used or encountered a diagnostic product that has been deficient in some area. In some cases, those products have been deficient in performance because of faulty manufacture of a component or reagent, rather than inappropriate design or specifications. In general, deficiencies are detected by quality-assurance programs, clinical feedback, and operator vigilance.
The benefits of CLIA '88, derived from increased requirements for calibration and for regulation and certification of tests permitted in a laboratory, will be difficult to measure. However, users will view the regulations in various ways: #{149} Operators will perceive an attempt to improve safety and reliability, while at the same time questioning cost effectiveness.
#{149} Institutions
will be concerned about situations that can jeopardize operation of an approved facility that can lose recognition for federal reimbursement. #{149} Patients will notice very little except increased costs.
Impactof Legislationon the Future
The most constant feature of the diagnostic industry during the past three decades has been change: change in technology, product style, and economics. It is imperative that federal legislation not inhibit this feature.
It is important that legislation change to keep pace with new-product development, allowing the rapid implementation of new, exciting, beneficial technology. As the role of new technological development increases, the need for flexibility becomes essential. It would be tragic if well-meaning legislation, aimed (e.g.) at the elimination of poorly performed pap tests, were to inhibit or delay the introduction of new products generally in the U.S. It would be of greater consequence if such practice further eroded U.S. dominance of this marketplace by permitting growth of development and marketplace elsewhere in the world. It is incumbent on the professional bodies within the U.S. medical profession to strive for flexible legislation that changes with, or anticipates, a rapidly changing industry and its technology.
